» Articles » PMID: 23246962

Identification of PY654-β-catenin As a Critical Co-factor in Hypoxia-inducible Factor-1α Signaling and Tumor Responses to Hypoxia

Overview
Journal Oncogene
Date 2012 Dec 19
PMID 23246962
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia is linked to epithelial-mesenchymal transition (EMT) and tumor progression in numerous carcinomas. Responses to hypoxia are thought to operate via hypoxia-inducible factors (HIFs), but the importance of co-factors that regulate HIF signaling within tumors is not well understood. Here, we elucidate a signaling pathway that physically and functionally couples tyrosine phosphorylation of β-catenin to HIF1α signaling and HIF1α-mediated tumor EMT. Primary human lung adenocarcinomas accumulate pY654-β-catenin and HIF1α. All pY654-β-catenin, and only the tyrosine phosphorylated form, was found complexed with HIF1α and active Src, both within the human tumors and in lung tumor cell lines exposed to hypoxia. Phosphorylation of Y654, generated by hypoxia mediated, reactive oxygen species (ROS)-dependent Src kinase activation, was required for β-catenin to interact with HIF1α and Src, to promote HIF1α transcriptional activity, and for hypoxia-induced EMT. Mice bearing hypoxic pancreatic islet adenomas, generated by treatment with anti-vascular endothelial growth factor antibodies, accumulate HIF1α/pY654-β-catenin complexes and develop an invasive phenotype. Concurrent administration of the ROS inhibitor N-acetylcysteine abrogated β-catenin/HIF pathway activity and restored adenoma architecture. Collectively, the findings implicate accumulation of pY654-β-catenin specifically complexed to HIF1α and Src kinase as critically involved in HIF1α signaling and tumor invasion. The findings also suggest that targeting ROS-dependent aspects of the pY654-β-catenin/ HIF1α pathway may attenuate untoward biological effects of anti-angiogenic agents and tumor hypoxia.

Citing Articles

NOX1 and PRDX6 synergistically support migration and invasiveness of hepatocellular carcinoma cells through enhanced NADPH oxidase activity.

Lagal D, Barcena J, Requejo-Aguilar R, Padilla C, Leto T Adv Redox Res. 2023; 9.

PMID: 37900981 PMC: 10611439. DOI: 10.1016/j.arres.2023.100080.


A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF colorectal tumors.

Ruiz-Saenz A, Atreya C, Wang C, Pan B, Dreyer C, Brunen D Nat Cancer. 2023; 4(2):240-256.

PMID: 36759733 PMC: 9970872. DOI: 10.1038/s43018-022-00508-5.


Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling.

Shah K, Kazi J Front Oncol. 2022; 12:858782.

PMID: 35359365 PMC: 8964056. DOI: 10.3389/fonc.2022.858782.


Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma.

Huang K, Yue X, Zheng Y, Zhang Z, Cheng M, Li L Front Oncol. 2021; 11:726745.

PMID: 34540695 PMC: 8446619. DOI: 10.3389/fonc.2021.726745.


Advanced glycation end products induce endothelial hyperpermeability via β-catenin phosphorylation and subsequent up-regulation of ADAM10.

Weng J, Chen Z, Li J, He Q, Chen D, Yang L J Cell Mol Med. 2021; 25(16):7746-7759.

PMID: 34227224 PMC: 8358892. DOI: 10.1111/jcmm.16659.


References
1.
Turley E, Veiseh M, Radisky D, Bissell M . Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?. Nat Clin Pract Oncol. 2008; 5(5):280-90. PMC: 2846172. DOI: 10.1038/ncponc1089. View

2.
Littlepage L, Sternlicht M, Rougier N, Phillips J, Gallo E, Yu Y . Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res. 2010; 70(6):2224-34. PMC: 2840052. DOI: 10.1158/0008-5472.CAN-09-3515. View

3.
De Bock K, Mazzone M, Carmeliet P . Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. Nat Rev Clin Oncol. 2011; 8(7):393-404. DOI: 10.1038/nrclinonc.2011.83. View

4.
Luo D, Wang J, Li J, Post M . Mouse snail is a target gene for HIF. Mol Cancer Res. 2011; 9(2):234-45. DOI: 10.1158/1541-7786.MCR-10-0214. View

5.
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F . Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15(3):220-31. PMC: 2874829. DOI: 10.1016/j.ccr.2009.01.027. View